Pinned straw:
Breaking down in simple terms it looks like this drug that Corvus has breaks down the immuno-resistance of prostate cancer tumors so it can be more easily treated against Immunotherapy
That's my interpretation - others may have different way of reading it.
Potentially big against targeted radiotherapy like Telix and Lantheus (and that "other company") especially for patients that can't tolerate radiation.
But this is still early stage with 30% reduction in PSA.
Surprised no one is covering this. But not surprised this no revenue company is now soaring past a diluted market cap of $1bn.
Too bad I didn't buy when this was just over $100m USD.
Very interesting....